Enhanced tumour cell nuclear targeting in a tumour progression model by unknown
Nastasie et al. BMC Cancer  (2015) 15:76 
DOI 10.1186/s12885-015-1045-zRESEARCH ARTICLE Open AccessEnhanced tumour cell nuclear targeting in a
tumour progression model
Michael S Nastasie1, Helmut Thissen2, David A Jans1 and Kylie M Wagstaff1*Abstract
Background: There is an urgent need for new approaches to deliver bioactive molecules to cancer cells efficiently
and specifically.
Methods: Here we fuse the cancer cell nuclear targeting module of the Chicken Anaemia Virus Apoptin protein to
the core histones H2B and H3 and utilise them in transfection, protein transduction and DNA binding assays.
Results: We found subsequent nuclear accumulation of these proteins to be 2–3 fold higher in tumour compared
to normal cells in transfected isogenic human osteosarcoma and breast tumour progression models. This represents
the first demonstration of enhanced nuclear targeting by Apoptin in a tumour progression model, and its
functionality in a heterologous protein context. Excitingly, we found that the innate transduction ability of histones
could be exploited in combination with the Apoptin nuclear targeting module to effect an overall 13-fold higher
delivery of protein to osteosarcoma cancer cell nuclei compared to their isogenic normal counterparts.
Conclusions: This is the first report of cancer-cell specificity by a cell penetrating protein, with important implications
for the use of protein transduction as a vehicle for gene/drug delivery in the future, and in particular in the development
of highly specific and effective anti-cancer agents.
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proteinBackground
Despite modest recent decreases in incidence rates due
to preventative life style choices, cancer remains one of
the most prevalent causes of death in both developed
and developing countries [1-3]. The principal difficulty
in achieving efficient anti-cancer treatment, whether by
chemotherapy, radiotherapy or even excision surgery,
has always been in administering the therapy specifically
to tumour cells without affecting healthy bystander cells
[4-8]. Since cancer cells derive from normal cells and as
such share numerous biological/genetic features, target-
ing one without affecting the other is extremely difficult.
A protein that has attracted interest in this context is
viral protein 3 (VP3, also known as Apoptin) from
chicken anaemia virus (CAV), which shows enhanced
nuclear targeting abilty in tumour compared to normal
cells [9-12]. In most cases, Apoptin can also elicit* Correspondence: kylie.wagstaff@monash.edu
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unless otherwise stated.apoptosis in cancer cells [11,13], whereas nuclear trans-
location of Apoptin does not appear to be sufficient to
mediate apoptosis in normal cells [14]. Interestingly,
Apoptin nuclear translocation can be triggered in re-
sponse to DNA damage in normal cells, while blocking
these pathways in transformed cells can rescue them
from Apoptin-induced cell death [13]. The N-terminal
69 amino acids of Apoptin appear to be responsible for
mediating at least some of Apoptin’s cell death pathways
[14], whereas the tumour selective nuclear targeting abil-
ity of Apoptin has been localised to its C-terminal
domain (amino acids 74–121) [15-17], known as the
tumour cell enhanced nuclear targeting signal (tNTS).
The tNTS contains two NLS regions (a.a. 82–88; 111–
121) [14,18,19], as well as an exportin-1 (CRM-1) recog-
nised nuclear export sequence (NES a.a. 97–105) which
is inhibited by specific phosphorylation of threonine 108
in cancer cells [15,16,18,20]. Importantly, the Apoptin
tNTS region accouns for only ~20% of Apoptin’s proa-
poptotic ability in cancer cells [14]. The ability of thel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with only minimal toxicity makes it an attractive target-
ing moiety because of this additional layer of safety by
comparison with full length Apoptin. The Aptoptin
tNTS is unique in terms of potential as the basis of
cancer therapies specifically targeting the nuclei of
tumour cells [3,9].
In this study we examine the tumour-selective nuclear
targeting ability of the Apoptin tNTS in isogenic tumour
and normal cells as well as an isogenic tumour progres-
sion cell model. Since the lines derive from the same
genetic background, conclusions can be drawn relating
directly to tumorigenic status, without confounding dif-
ferences in genetic or cell type factors. Utilising this
powerful system, we show that the tumour-selective nu-
clear targeting ability of the Apoptin tNTS can function
in the heterologous protein context of core histones;
core histones are strongly nuclear [21], being responsible
for DNA compaction in the nucleus of all eukaryotic
cells, meaning that this is, the first demonstration of the
ability of the tNTS to function in the context of a highly
nuclear protein. In addition, we investigate tNTS activity
in the MCF10A breast tumour progression model, dem-
onstrating selectivity for well-progressed tumour pheno-
types and highlighting its potential for use in specific
anti-cancer treatments in the future. Finally, we show
that the tNTS is functional in tumour-selective nuclear
targeting in the context of bacterially expressed recom-
binant histones that retain protein transduction proper-
ties, and hence have exciting therapeutic potential.
Histones are well-established as being able to undergo
protein transduction, and hence possess utility as gene/
drug delivery vehicles. The addition of the tNTS to his-
tones thus represents an exciting step forward in the devel-
opment of tumour-specific anti-cancer therapies [21-25].Methods
Generation of GFP-fusion protein mammalian cell
expression plasmids
Gateway cloning technology and the pDest53 vector
(Invitrogen) were used to generate mammalian expres-
sion vectors encoding green fluorescent protein (GFP)
fused to Xenopus histones H2B or H3. The optimised
nuclear localisation signal (NLS) from the SV40 large
tumour antigen (Op-T-NLS) or the C-terminus of Apop-
tin (residues 74–121; tNTS) were fused to either histone
H2B or histone H3 using primers designed for overlap
extension polymerase chain reactions. These were then
introduced into either the pDest53 or pTrcHisA-EGFP
vector (Invitrogen and Novagen respectively) using
Gateway cloning technology as previously described
[21]. The fidelity of all constructs was confirmed by
DNA sequencing (see Additional 1: Figure S2C). pEGFP(Clontech) and pEPI-tNTS [16] vectors were used to ex-
press GFP and GFP-tNTS in mammalian cells respectively.Mammalian cell culture and transfection
SAOS-2 cells were cultured in McCoys 5A medium
(modified) (Sigma-Aldrich) supplemented with 2.2 g/l
sodium bicarbonate, 10% heat inactivated foetal calf
serum (FCS) and 1 mM sodium pyruvate. SR5 and SR40
cells were cultured in the above medium with an add-
itional 800 μg/ml Geneticin (GIBCO) as a selective
agent. MCF10A, MCF10AT and MCF10CA1h cells were
cultured in DMEM/F12 medium with 10 mM HEPES
(Sigma), supplemented with 2.2 g/l sodium bicarbonate,
5% horse serum, 100 ng/ml cholera toxin (Sigma), 0.5 μg/
ml hydrocortisone, 10 μg/ml bovine insulin and 20 ng/ml
human epidermal growth factor (EGF) (GIBCO). All cells
were grown at 37°C in 5% CO2. Cells were seeded onto
glass coverslips (13 mm in diameter or 15 X 15 mm) 24 h
prior to transduction experiments or transfection con-
ducted using 4 μg of DNA complexed with 10 μl Lipofec-
tAMINE 2000™ (Invitrogen) per well of a 6-well tissue
culture plate, according to the manufacturer’s instructions.Microscopy and image analysis
Cells were imaged 6–9 hours post transfection by con-
focal laser scanning microscopy (CLSM; Olympus
FV1000) using a 100 X oil immersion objective. The
ImageJ v1.43u public domain software was used to ana-
lyse digitised images to determine the ratio of nuclear
(Fn) to cytoplasmic (Fc) fluorescence ratio (Fn/c) ac-
cording to the formula: Fn/c = (Fn-Fb)/(Fc-Fb), where Fb
is background autofluorescence [21]. An Fn/c value > 1
indicates nuclear accumulation, whereas < 1 indicates
cytoplasmic localisation. An Fn/c value of 1 indicates
diffuse localisation, with an equivalent amount of protein
in both the cytoplasm and the nucleus. To perform a
student’s t-test for statistical analysis, Microsoft Excel™
software was used.Recombinant protein expression AND purification
The fusion proteins GFP-H3, GFP-H3-tNTS or GFP-
H2B-tNTS (expressed from plasmid pTrcHisA-EGFP
(Novagen) [26]) were expressed and purified from bac-
teria as (His)6-tagged proteins using nickel affinity chro-
matography under denaturing conditions (8 M urea) and
proteins were eluted in dimerization buffer as previously
described [21,23]. Protein purity was c. 70%, based on
Coomasie staining of SDS-PAGE (see Additional 1:
Figure S2A); although limited degradation products were
present, only full-length protein was incorporated into
DNA binding histone tetramers (Additional 1: Figure S2B).
(His)6-tagged GFP protein was made as previously [27].
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Recombinant proteins at increasing concentrations were
incubated with 300 ng of linearised plasmid DNA (6.7 KB)
for 30 minutes at room temperature. Samples were then
subjected to electrophoresis in a 0.8% ethidium-free agar-
ose gel at 40 V for 16 h at 4°C in TAE (40 mM Tris,
0.114% glacial acetic acid, 1 mM ethylenediaminetetraace-
tic acid (EDTA), ph7.5). After staining with ethidium
bromide, the gel was visualised under UV illumination.
Protein transduction
Cells seeded on 13 mm diameter glass coverslips in 24
well plates and 500uL media, were treated with 100uL of
7uM GFP-fusion protein in DMEM for 4 hours at 37°C.
The media was removed and the cells washed using
phosphate buffered saline (PBS) kept at 37°C to remove
free protein. Cells were then treated with DMEM lacking
phenol red, containing 1.25ug/mL Hoescht stain for
30 minutes. After thorough washing in a pool of warm
PBS and imaging using CLSM as per mammalian cell
transfection (above), ImageJ was used to convert the
‘.oif ’ files into Tiff format. CellProfiler (r10997) public
domain software was used to automatically identify nu-
clei based on Hoescht staining in the blue channel and
measure the relative concentration (as mean fluores-
cence) of recombinant protein present in those areas
using GFP fluorescence indicated in the green channel.
Additional methods
Please see Additional file 2 for materials and methods
related to the Supplementary Figures.
Results
The Apoptin tNTS confers tumour cell selectivity to
histones H2B and H3
Although the Apoptin tNTS has been shown to be able to
confer tumour-cell selective nuclear targeting onto heterol-
ogous proteins such as GFP [18,28], it has never been con-
firmed to confer tumour-cell selectivity to proteins that are
intrinsically able to accumulate to high levels in the nu-
cleus. Due to their essential role in DNA compaction and
transcriptional regulation, histone proteins contain very
strong endogenous NLSs and undergo rapid nuclear im-
port during s-phase such that they are found exclusively in
the nucleus and do not normally undergo nuclear export
[29]. We generated mammalian and bacterial expression
vectors which contain a GFP moiety fused to the N-
terminus of either histone H2B or H3 and which also con-
tain either the Apoptin tNTS or an optimised version of
the SV40 large tumour antigen NLS (Op-T-NLS) fused to
their C-terminus (see Figure 1A for schematic).
For rigorous assessment of tumour cell selective target-
ing, we utilised isogenic normal/tumour cell line pairs that
are derived from a common origin and differ only in theirtumorigenic status, including the well-characterised SR5
(SR40)/SAOS-2 osteosarcoma cell pair, which has previ-
ously been used to characterise the Apoptin tNTS [16].
SAOS-2 cells contain a nonsense mutation in the retino-
blastoma (Rb) gene, with ectopic expression of full length
Rb restored in the SR5 and SR40 non-tumorigenic cell
lines [30-33], where stable expression of wild type Rb for
up to four months is known not to cause any detrimental
effects, apart from an increase in cell size and a significant
decrease in proliferation [30] consistent with Rb’s cell
cycle role [32,33]. We also used a breast tumour progres-
sion model, based on the spontaneously immortalized
non-tumorigenic MCF10A normal human breast epithe-
lial line [34]. MCF10A cells have been transformed to
express the activated c-Ha-ras oncogene to generate the
pre-malignant MCF10AT cell line [35,36], which in turn
has been used to generate the MCF10CA1h cell line sub-
sequent to selection through xenograft implant in mice
[37]. The MCF10AT cell line expresses significantly higher
levels of p21 ras protein, as well as the ability to grow in
anchorage independent fashion in the absence of growth
factors [36]. MCF10AT are pre-malignant, able to generate
only small nodules in nude mice, representative of benign
simple ducts, with < 25% of xenografts progressing to car-
cinomas [35,36]. In contrast to the MCF10AT line,
MCF10CA1h xenografts rapidly form well-differentiated
large carcinomas in 100% of mice with no evident precur-
sor stage [37]. This set of cell lines represents a wide
spectrum of neoplastic progression including benign, pre-
malignant and malignant cell lines, and has previously
been used to elucidate differences between normal and
cancer cell nuclear import [37,38].
SR5 and SAOS-2 cells were transfected to express GFP-
H3, GFP-H3-tNTS and GFP-tNTS and examined live
using confocal laser scanning microscopy (CLSM;
Figure 1B). As has been previously reported, GFP-tNTS
alone accumulated in the nucleus of the tumorigenic
SAOS-2 cells to a greater extent than in the non-
transformed SR5 line, as evident from the increased
cytoplasmic fluorescence. This was confirmed by image
analysis of digitised images to measure the nuclear to
cytoplasmic fluorescence ratio (Fn/c, Methods: Figure 1C;
where Fn/c > 1 indicates nuclear accumulation), indicating
a significantly higher level (c. 2 fold, p < 0.01) of nuclear
accumulation in the tumorigenic SAOS-2 cells, compared
to the non-transformed SR5 cells. In contrast, GFP-H3
was almost exclusively nuclear in both lines, with little to
no visible cytoplasmic fluorescence evident (Figure 1B).
Quantitative analysis confirmed that there was no signifi-
cant difference in the nuclear accumulation of GFP-H3
between the two cell lines. Excitingly, the addition of the
tNTS to GFP-H3 significantly increased the nuclear accu-
mulation of the histone in the tumorigenic SAOS-2 line
and not in non-transformed SR5 cells, indicating that the
Figure 1 The tNTS confers tumour cell selectivity to core histone variants. A. Schematic representation of the engineered histone H2B and
H3 proteins utilised in this study. GFP, Green Fluorescent Protein; H2B, histone H2B; H3, histone H3; Op-T-NLS, optimised NLS from the SV40 large
tumour antigen (T-ag); tNTS, C-terminal domain of Apoptin (aa 74–121). B. SR5 (normal) or SAOS-2 (tumour) cells were transfected to express the
indicated fusion proteins followed by CLSM analysis 6 h post-transfection. C. Analysis of digitised images such as those shown in B was used to
determine the relative levels of nuclear accumulation as described in materials and methods. Results represent the mean Fn/c ± SEM (n > 10) and
p values indicate significant differences as determined by the students t-test. D. Cancer comparative indexes (CCI) of the results shown in C,
determined from a ratio of the Fn/c values. E. SR40 (normal) or SAOS-2 (tumour) cells were transfected to express the indicated fusion proteins
and imaged by CLSM 6 h post-transfection. F. Images such as those in E were analysed as per C to determine the Fn/c ratio. G. CCI’s calculated
as per D from the results in F.
Nastasie et al. BMC Cancer  (2015) 15:76 Page 4 of 11tNTS can confer tumour-cell selective activity even when
in the context of a highly nuclear heterologous protein, in-
dicating for the first time that histones can be manipu-
lated to target preferentially to the nuclei of tumour cells.
The Cancer Comparative Index (CCI) [39], the ratio of
the Fn/c of the protein in tumour compared to normal
cells (where a CCI greater than 1 denotes increased nu-
clear accumulation in tumour cells), was 1.7 for GFP-tNTS (Figure 1D), consistent with previous observations
[16,39], whilst GFP-H3 had a CCI of c. 1.0, indicating no
cancer specificity. In contrast, GPF-H3-tNTS had a CCI
of 1.8, comparable to that for GFP-tNTS, demonstrating
clearly that tumour-selective targeting can be transferred
to nuclear proteins such as histones.
To confirm that the enhanced tumour-cell selectivity
shown here is not a specific property of histone H3, the
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(Figure 1E-G). In comparable fashion to the results for
H3, GFP-H2B was predominantly nuclear to the same
extent in SR40 and SAOS-2 cells (CCI of 1.0), but the
presence of the tNTS resulted in significantly higher nu-
clear accumulation in SAOS-2 transformed cells (CCI of
2.7, p < 0.001). Clearly, the Apoptin tNTS has enhanced
cancer cell nuclear targeting ability that is transferrable
to proteins such as histones H3 and H2B, that normally
have no inherent ability to accumulate to a higher extent
in the nuclei of tumour versus normal cells.
Apoptin tNTS enhanced nuclear targeting in a tumour
progression model
We next tested tNTS dependent targeting in the
MCF10A breast tumour progression model. CLSM
analysis of transfected cells expressing the GFP-tNTSFigure 2 Tumour cell enhanced nuclear targeting conferred by the A
model and can be conferred to histones H3 and H2B. A. MCF10A (norm
transfected for 6 h to express the indicated fusion proteins followed by CL
determine relative levels of nuclear accumulation displayed as mean Fn/c ± S
the students t-test. C. CCIs of the results shown in B, determined from a ratio
series of three similar experiments. D. MCF10A (normal), MCF10AT (pre-malign
the indicated fusion proteins. E. Digitised images as those shown in D were a
as mean Fn/c ± SEM (n > 40) where p values indicate significant differences d
determined from a ratio of the Fn/c values. Results are from a single typical econstruct alone revealed a significant (p < 0.001) increase
(almost 2-fold) in nuclear accumulation for GFP-tNTS
in MCF10CA1h tumorigenic cells compared to both
normal MCF10A and pre-malignant MCF10AT cells
(Figure 2A-C). The almost 3 CCI indicated high cancer
cell specificity, the first demonstration of tumour cell
specific targeting by the Apoptin tNTS in a human
breast cancer progression model. That the Apoptin
tNTS displays a strong preference for more advanced
tumour phenotypes, highlights its potential effectiveness
as a tumour targeting moiety for cancer-therapeutics.
To confirm that the tumour selective activity of Apop-
tin can be conferred to histone proteins in this breast
tumour model system, the engineered histone H3 con-
structs were expressed in the MCF10A isogenic cell
series. As observed for the SR5/SAOS-2 cell line pair,
GFP-H3 did not show a significant difference in nuclearpoptin-tNTS is observed in a breast cancer tumour progression
al), MCF10AT (pre-malignant) or MCF10Ca1h (tumour) cells were
SM analysis. B. Digitised images as those shown in A were analysed to
EM (n > 40) where p values indicate significant differences determined by
of the Fn/c values. Results are from a single typical experiment from a
ant) or MCF10Ca1h (tumour) cells were transfected for 6 h to express
nalysed to determine relative levels of nuclear accumulation displayed
etermined by the students t-test. F. CCIs of the results shown in E,
xperiment from a series of two similar experiments.
Figure 3 Engineered histone H3 proteins bind to DNA. The
indicated recombinant proteins were incubated at increasing
concentrations (left to right; 0.1, 0.25, 0.5, 0.75 and 1 μM for the
histone proteins and 0.5 and 1 μM for GFP) with 300 ng of linearised
plasmid DNA (6.7 KB) for 30 min at room temperature prior to
electrophoresis (40 V) at 4°C for 16 h against DNA alone (−). GFP
alone was also incubated with DNA in the same way. Results are
from a single typical experiment from a series of two
similar experiments.
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GFP-H3-tNTS showed significantly (p < 0.01) higher nu-
clear accumulation in MCF10CA1h cells compared to
either the MCF10A normal or the MCF10AT pre-
malignant cells (Figure 2B). Further, the CCI of GFP-
H3-tNTS suggests that the protein accumulates to a >2
fold higher extent in the nuclei of the tumorigenic
MCF10CA1h cells compared to the MCF10A, non-
transformed cells (Figure 2C). Excitingly, this demon-
strates for the first time that the tumour cell nuclear
targeting ability of the tNTS can be transferred to heter-
ologous proteins in a model which closely resembles hu-
man proliferative breast disease with increasing targeting
preference in the more advanced stages of breast tumour
progression. To demonstrate that this activity is exclu-
sively dependent on the tNTS sequence and not merely
the result of the addition of an exogenous NLS to the
histone protein, we replaced the Apoptin tNTS with the
optimised version of the SV40 large-tumour antigen
(Op-T-NLS), which has previously been shown to in-
crease the nuclear accumulation of other core histone
proteins [21]. Although, the nuclear accumulation of
GFP-H3-Op-T-NLS was significantly elevated compared
to GFP-H3 alone, the increase was comparable across
the MCF10A, MCF10AT and MCF10CA1h cell lines,
with no significant difference in Fn/c observed
(Figure 2B, C), confirming that the tumour-cell selective
activity of these novel histones is not a general feature of
NLSs but a unique property of the Apoptin tNTS.
Tumour-cell selective nuclear targeting can also be
conferred to histone H2B in the tumour progression
model
To confirm that the results observed in the breast
tumour progression model were not specific to histone
H3, histone H2B was also examined in the same way.
Whereas GFP-H2B and GFP-H2B-Op-T-NLS showed no
significant difference in their nuclear accumulation be-
tween the MCF10A, MCF10AT and MCF10CA1h cells
(Figure 2D-F), the nuclear accumulation of GFP-H2B-
tNTS was significantly (p < 0.001) higher in the tumori-
genic MCF10CA1h cells compared to the other cell
types, with a CCI of >2 (Figure 2C). The level of tumour
cell selectivity observed for GFP-H2B-tNTS is nearly
identical to that observed for GFP-H3-tNTS in this cell
system, implying that tumour cell selective activity is de-
rived specifically from the Apoptin tNTS. It thus seems
likely that robust tumour-cell specificity can be con-
ferred by the tNTS to other heterologous proteins.
Recombinant histone proteins retain DNA binding ability
when fused to the tNTS
The ability of histones to bind DNA is critical to their
use as DNA delivery vectors for future gene therapyapplications [21]. To confirm that the DNA binding cap-
acity of our novel tumour selective fusion proteins is not
impaired by the addition of the tNTS, recombinant
GFP-H3, GFP-H3-Op-T-NLS and GFP-H3-tNTS fusion
proteins were examined in a DNA electrophoretic
mobility shift assay. Linearised plasmid DNA was incu-
bated with increasing concentrations of the recombinant
proteins and subjected to agarose gel electrophoresis
followed by ethidium bromide staining and UV illumin-
ation to visualise the DNA bands (Figure 3). DNA bind-
ing in this assay is evidenced by a retardation of the
movement of the DNA through the agarose gel. GFP-H3
and GFP-H3-Op-T-NLS were able to retard the move-
ment of the linearised DNA to a similar extent, indica-
tive of comparable DNA binding ability. Interestingly,
GFP-H3-tNTS DNA binding ability appeared to alter
bands whilst at lower concentrations of protein, indicat-
ing a higher binding to DNA. This is consistent with
wild type histone H3 having the highest DNA binding
ability of the four core histones, whereby histone H3
binds to the DNA so strongly that it is unable to enter
the gel and remains in the well (Additional 1: Figure S1).
Histones containing the tNTS can enter into intact cells
via protein transduction and exhibit tumour specific
nuclear targeting ability
Histones are members of the cell penetrating family of
proteins possessing innate protein transduction ability,
enabling them to pass through the plasma membrane of
cells in an energy and receptor-independent mechanism,
a further property of great utility in gene therapy app-
lications [21,23,40,41]. Based on the high CCI index
observed in transfected cells, the GFP-H3 and GFP-H3-
tNTS based constructs were selected to test whether the
tNTS fusion proteins generated here have potential for
tumour selective delivery in a protein transduction assay.
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combinant GFP, GFP-H3 or GFP-H3-tNTS recombinant
proteins. Cells were then washed extensively to remove
extracellular protein, stained with Hoechst and imaged
live via CLSM (Figure 4A). As GFP itself does not pos-
sess any natural protein transduction potential the level
of fluorescence in the nucleus of these samples did not
differ significantly from the PBS alone control (not
shown), as expected. Strikingly, the level of fluorescence
of GFP-H3 quantitated in the SAOS-2 transformed cell
line nuclei was increased by c. 350% compared that ob-
served in the non-transformed counterpart (after taking
into account background) (Figure 4B) which represents
a CCI of > 4 (Figure 4C), indicating tumour specific nu-
clear accumulation in the absence of the tNTS, most
likely attributable to differences in the protein transduc-
tion capacity of GFP-H3 in the two lines, with much
more total protein taken up by the tumour cells in gen-
eral thereby leading to a higher level of nuclear fluores-
cence (Figure 4A). This is the first report of cell
specificity for histone-mediated protein transduction,
which had previously been thought to be similar in all
cells [21,41]. Excitingly, this is also the first report of in-
nate tumour cell selectivity for a protein transduction
domain containing protein. This result was confirmed by
subcellular fractionation experiments (Additional 1:
Figure S3), whereby GFP-H3 and GFP-H3tNTS could not
be detected in the SR5 normal cells under the conditions
used, but were readily observed in the tumour cells.
GFP-H3-tNTS showed an even more dramatic differ-
ence in the level of nuclear fluorescence in the tumour
cells compared to normal cells (Figure 4A), with a CCI
of 13 (Figure 4C). Similar results were observed for
GFP-H2B-tNTS (CCI of 11, not shown), confirming that
this activity is not specific to histone H3. It is interesting
to note that the additional tumour selective ability con-
ferred by the tNTS did not appear to be due to an in-
crease in protein concentration in the nucleus of the
transformed SAOS-2 cells, but rather, was the result of a
decrease in protein concentration in the nucleus of the
normal SR5 cells (Figure 4B). These results confirm that
the nuclear export activity of the tNTS on highly nuclear
proteins such as histones in normal cells is retained in
the purified recombinant fusion proteins and further-
more this affect is enhanced synergistically when using
proteins that already harbour innate tumour cell select-
ivity as was observed here for the first time for histones.
Discussion
Current cancer treatments are often associated with de-
bilitating side-effects on the surrounding healthy tissue
and ultimately the patient due to the lack of specificity
of anti-cancer chemotherapy, radiotherapy or amputa-
tion/excision surgery, which take advantage of specificattributes endemic to tumours such as an increased level
of cellular proliferation, but which are often also present
in normal tissues, such as the rapidly proliferating cells
of the bone marrow. The Apoptin protein from chicken
anaemia virus however shows selectivity in tumour com-
pared to normal cells, with increased nuclear accumula-
tion in tumour cells. Here we investigate a novel use of
the Apoptin protein, by isolating its tumour cell selectiv-
ity and utilising it to generate tumour-cell selective
proteins. We used a human breast cancer tumour pro-
gression model, to examine the nuclear localisation of
the Apoptin tNTS for the first time, showing that the
tNTS is significantly more nuclear in the tumorigenic
MCF10CA1h cell line compared to the normal MCF10A
or the MCF10AT pre-malignant isogenic counterparts.
This underlines the fact that Apoptin’s nuclear localization
specificity is imparted by the tNTS and can be conferred
on heterologous proteins which are normally exclusively
nuclear. Presumably this specificity is due to increased ex-
port of the Apoptin tNTS in normal cells [16].
We have shown here using two different normal/
tumour isogenic cell type models that the Apoptin tNTS
was able to increase the nuclear accumulation of his-
tones H3 and H2B specifically in cancer cells but not in
normal isogenic counterparts, with a preference for ad-
vanced tumour phenotypes similar to the Apoptin tNTS
alone. Whilst the tNTS has previously been fused to
GFP and maltose-binding-protein (MBP) for tracking
purposes, resulting in their cancer cell specific localisa-
tion [15,16,42], it has not previously been fused to a
highly nuclear protein such as a histone. Thus, we show
here for the first time that the tNTS is sufficient to im-
part cancer cell nuclear specificity upon histone proteins
and we predict that this will be consistent for other nu-
clear proteins, which could have a great impact on the
development of future specific nuclear delivery of cancer
therapeutics.
In this study we were also able to demonstrate that the
addition of the tNTS moiety enhances the DNA binding
ability of the recombinant GFP-tagged histone protein,
indicating that the tNTS moiety itself is capable of medi-
ating some DNA binding. The fact that the Op-T-NLS,
containing several positive residues, does not enhance
DNA binding here indicates that the contribution to
DNA binding shown by the tNTS is specific. This is
consistent with previous literature which showed that
Apoptin is able to bind DNA [43] and the effect here
may be assumed to be a summative one. The implica-
tions of this may be far reaching, as previously the focus
when using the tNTS was on its cancer specific nuclear
delivery capabilities, we show here for the first time that
it is likely to provide dual benefit when incorporated
into vectors being engineered for gene therapy applica-
tions. Similarly, although we have not observed any
Figure 4 (See legend on next page.)
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Figure 4 Innate tumour cell selectivity is exhibited by the recombinant histone H3 protein and is further enhanced by the Apoptin-tNTS.
A. SR5 (normal) or SAOS-2 (tumour) cells were incubated for 4 hours in media containing 1.17 μM indicated recombinant protein. Cells were then
washed with warm 37°C PBS and treated with DMEM lacking phenol red, containing 1.25 μg/mL Hoescht stain for 30 min. Cells were thoroughly
washed in warm PBS and imaged using CLSM as per mammalian cell transfection (above). The blue channel shows Hoescht stained nuclei and the
green channel shows the uptaken GFP-tagged recombinant protein. Blue (Hoescht) and Green (GFP) channels are presented separately in grayscale
and merged in colour for clarity. B. Analysis of digitised images such as those in A was used to determine the relative mean fluorescence in the
nucleus of cells as described in Materials and Methods. The mean fluorescence value was then normalised to the GFP value representing background
fluorescence in each cell line. C. The data in B was used to calculate CCI values for GFP-H3 and GFP-H3tNTS recombinant proteins, relative to GFP
alone (as disregarded background). Results are from a single typical experiment from a series of two similar experiments.
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induced tumour-specific apoptosis that might occur in
therapeutic applications would have a comparable addi-
tive benefit in terms of tumour cell killing.
Perhaps the most interesting finding from this study
was that histone H3 exhibits innate cancer specific
transduction potential. This is the first report of cancer
specific transduction capacity for histones, and for in-
nate tumour selectivity in a protein transduction domain
in general, which further highlights their potential as
gene delivery vectors, especially with respect to cancer
therapeutics. When recombinant fusion proteins were
delivered to cells via protein transduction, the addition
of the tNTS to histone H3 (or histone H2B, not shown)
resulted in a synergistic effect that allowed for 13 fold
higher nuclear accumulation of the protein in the trans-
formed SAOS-2 cells compared to the normal SR5 iso-
genic counterparts. The affect of the tNTS was due to a
decrease in protein concentration in the nucleus of the
normal SR5 cells rather than an increase in the SAOS-2
transformed cell line. This is consistent with the tNTS
being actively exported from the nucleus by an exportin-
1 dependant mechanism in normal cells. In transformed
cell types, however, nuclear export mediated by the
tNTS is inhibited through phosphorylation of Threo-
nine108 [15,16]. The results here suggest that the tNTS
is functional even when included within a fusion protein
delivery system.
There are many physiological examples in which the
extent of nuclear accumulation rather than the simple
presence or absence of a protein in the nucleus is a key
driver, such as in developmental processes or signal
transduction and so these novel vectors may prove quite
useful even before complete specificity is achieved. Ex-
amples include human sex determination and nuclear
concentration of the SRY/SOX9 transcription factors
(where c. 2-fold differences in Fn/c represent the basis
of male/female sex determination) [44-47] and in neur-
onal cell function with respect to the NFkB p65 tran-
scription factor (see [48]). The nuclear levels of specific
viral proteins have been shown to be critical during viral
infection for a range of viral pathogens, including CMV
[49], porcine reproductive and respiratory syndrome
virus [50], respiratory syncytial virus [51] and dengue[52]. Importantly, threshold levels of nuclear accumula-
tion are critical for effective cancer gene/drug treatment
strategies for numerous systems (see [53]), such as the
first-line anti-cancer drug doxorubicin [54] meaning that
a >10 fold increase in nuclear accumulation exhibited by
histones engineered in this study may prove very valu-
able factors in the future for anti-cancer therapeutics.
Using recombinant histone vectors from this study in
preliminary gene delivery experiments we have already
achieved transfection in transformed cell lines (not
shown), further highlighting their potential for use in fu-
ture cancer targeted gene delivery strategies in addition
to their potential for directed transport of drug/peptide
cargo to cancer cell nuclei.
Conclusions
In conclusion, we used here for the first time a human
breast tumour progression model to demonstrate that
the nuclear accumulation of the Apoptin tNTS is signifi-
cantly higher in transformed cells compared to their
normal isogenic counterparts and that this activity can
be conferred to histones H3 and H2B which we have
also shown for the first time to possess innate cancer
targeting abilities. Whilst these histones may be further
developed to increase their specificity for tumours this
study highlights the power of the Apoptin tNTS and its
utility as a module for the development of a future class
of highly specific anti-cancer agents.
Additional files
Additional file 1: Figure S1. Wild type xenopus histone proteins bind
have distinct DNA binding abilties. A DNA gel mobility shift assay was
performed using the indicated proteins at increasing concentrations (0,
0.5, 0.75, 1 μM) and 300 ng of linearised plasmid DNA (pUC18) as per the
legend to Figure 3. GFP was used only at 1 μM. Results are from a single
typical experiment from a series of two similar experiments. Figure S2.
Validation of recombinant proteins generated in this study. A. 4 and 8 μg
of the indicated recombinant proteins was subjected to SDS-PAGE
followed by Coomassie staining and imaging on a UV-transilluminating
platform as described in materials and methods. M: Page Ruler molecular
weight marker B. Histone tetramers containing the indicated recombinant
H3 proteins and equimolar wild type Xenopus Histone H4 [2], were
separated using SDS-PAGE, stained and visualized as in A. C. Sequence
alignments of GFP-H3 (i) and GFP-H3-tTNS (ii) expression plasmids
compared to pre-engineered recombinant protein templates as described
in materials and methods. Figure S3. Nuclear/Cytoplasmic fractionation
Nastasie et al. BMC Cancer  (2015) 15:76 Page 10 of 11of SR5 and SAOS-2 cells transduced with recombinant histones demonstrates
tumour-cell specificity. SR5 and SAOS-2 cells transduced with the indicated
recombinant proteins (as per Figure 4) were subjected to nuclear/cytoplasmic
fractionation as described in the Additional file 2: Supplementary materials
and methods. Samples were subjected to SDS-PAGE and Western analysis
using anti-GFP and anti-actin primary antibodies and fluorescent secondary
antibodies.
Additional file 2: Supplementary Materials and Methods.
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